Evidence map›Paper›PMID 26171403›Full record

ArticleJournal of immunology research2015

Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction.

Annemarie Weissenbacher, Theresa Hautz, Michael Kimelman, Rupert Oberhuber, Hanno Ulmer, Claudia Bösmüller, Manuel Maglione, Stefan Schneeberger

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Annemarie WeissenbacherDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, Austria.
Theresa HautzDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, Austria.
Michael KimelmanDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, Austria.
Rupert OberhuberDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, Austria.
Hanno UlmerDepartment of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, 6020 Innsbruck, Austria.
Claudia BösmüllerDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, Austria.
Manuel MaglioneDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, Austria.
Stefan SchneebergerDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Innsbruck Medical University, 6020 Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alemtuzumab, an anti-CD52 T-cell and B-cell depleting monoclonal antibody, is established for induction therapy in renal transplantation (KTx). We herein provide a comparative analysis between alemtuzumab and basiliximab induction therapy and correlate lymphocyte depletion and recovery with the clinical course after KTx. This is a single center retrospective analysis of 225 patients/consecutive kidney transplantations treated with alemtuzumab for lymphocyte depletion and 205 recipients treated with basiliximab. Mean lymphocyte counts were 22.8 ± 9.41% before Tx and 2.61 ± 3.11% between week 1 and week 3 in the alemtuzumab group and 23.77 ± 10.42% before Tx and 13.92 ± 8.20% in the basiliximab group. Delayed graft function (DGF), cytomegalovirus (CMV) status, and recipient age showed a significant correlation with lymphocyte counts in the alemtuzumab group only. The outcome was read in reference to the velocity of lymphocyte recovery and in comparison to the control group. Lymphocyte counts early after transplantation, following alemtuzumab treatment, could be identified as a predictive factor for kidney function early after transplantation. A detailed analysis of phenotype and function of lymphocytes after alemtuzumab induction together with a correlation with the clinical course is warranted.

Indexed as

Kidney TransplantationAdultAgedAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBasiliximabFemaleGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsKidneyLymphocyte CountLymphocyte DepletionLymphocytesAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBasiliximabImmunosuppressive AgentsRecombinant Fusion Proteins

Identifiers

PMID26171403
PMCPMC4480808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.